Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease
Bisphosphonates such as alendronate, risedronate and zoledronate have revolutionised the treatment for osteoporosis and Paget’s disease. These drugs reduce fracture risk and probably mortality in patients with osteoporosis. However, they have a long in vivo half-life following cessation and may be a...
Gespeichert in:
| Veröffentlicht in: | Rheumatology international 2013-09, Vol.33 (9), p.2189-2198 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2198 |
|---|---|
| container_issue | 9 |
| container_start_page | 2189 |
| container_title | Rheumatology international |
| container_volume | 33 |
| creator | Wong, Peter K. Borromeo, Gelsomina L. Wark, John D. |
| description | Bisphosphonates such as alendronate, risedronate and zoledronate have revolutionised the treatment for osteoporosis and Paget’s disease. These drugs reduce fracture risk and probably mortality in patients with osteoporosis. However, they have a long in vivo half-life following cessation and may be associated with delayed dental healing and even the devastating complication of osteonecrosis of the jaw (ONJ). Extensive media attention highlighting this issue has caused much concern among patients and healthcare professionals. This paper seeks to provide treating clinicians with a balanced multi-disciplinary review of the available evidence pertaining to this issue and practical advice regarding prevention and management of ONJ. |
| doi_str_mv | 10.1007/s00296-013-2771-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1428268921</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1428268921</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-d116fd194b2c29671e2a0b2a2b133017b0b6c41b75f2837f84e3c5ebb0689a863</originalsourceid><addsrcrecordid>eNp1kE1LxDAQhoMo7rr6A7xIwYuXaCbpJu1RF79gxYuCt5C0090ubbI2XcR_b8quIoKHmSHkmXdmXkJOgV0CY-oqMMZzSRkIypUCqvbIGFKhKEj2tk_GDBSnWUwjchTCisW3lOyQjLiQU65yNiZPN3VYL_0QzvRIO2xiKRMfevQOi86HOiS-SvolJivzkdQucd7R1jT1whnXJzZiSVkHNAGPyUFlmoAnuzohr3e3L7MHOn--f5xdz2mRptDTEkBWJeSp5UU8QAFywyw33IIQcUnLrCxSsGpa8UyoKktRFFO0lsksN5kUE3Kx1V13_n2DoddtHQpsGuPQb4KGlGc8shwiev4HXflN5-J2A6VEyiXjkYItNRwcOqz0uqtb031qYHrwWm-91tFrPXitVew52ylvbIvlT8e3uRHgWyDEL7fA7tfof1W_AAYniHs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1427342602</pqid></control><display><type>article</type><title>Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Wong, Peter K. ; Borromeo, Gelsomina L. ; Wark, John D.</creator><creatorcontrib>Wong, Peter K. ; Borromeo, Gelsomina L. ; Wark, John D.</creatorcontrib><description>Bisphosphonates such as alendronate, risedronate and zoledronate have revolutionised the treatment for osteoporosis and Paget’s disease. These drugs reduce fracture risk and probably mortality in patients with osteoporosis. However, they have a long in vivo half-life following cessation and may be associated with delayed dental healing and even the devastating complication of osteonecrosis of the jaw (ONJ). Extensive media attention highlighting this issue has caused much concern among patients and healthcare professionals. This paper seeks to provide treating clinicians with a balanced multi-disciplinary review of the available evidence pertaining to this issue and practical advice regarding prevention and management of ONJ.</description><identifier>ISSN: 0172-8172</identifier><identifier>EISSN: 1437-160X</identifier><identifier>DOI: 10.1007/s00296-013-2771-7</identifier><identifier>PMID: 23652790</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Animals ; Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology ; Bisphosphonate-Associated Osteonecrosis of the Jaw - prevention & control ; Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy ; Bone Density - drug effects ; Disease Models, Animal ; Humans ; Medicine ; Medicine & Public Health ; Review ; Rheumatology</subject><ispartof>Rheumatology international, 2013-09, Vol.33 (9), p.2189-2198</ispartof><rights>Springer-Verlag Berlin Heidelberg 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-d116fd194b2c29671e2a0b2a2b133017b0b6c41b75f2837f84e3c5ebb0689a863</citedby><cites>FETCH-LOGICAL-c441t-d116fd194b2c29671e2a0b2a2b133017b0b6c41b75f2837f84e3c5ebb0689a863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00296-013-2771-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00296-013-2771-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,782,786,27933,27934,41497,42566,51328</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23652790$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wong, Peter K.</creatorcontrib><creatorcontrib>Borromeo, Gelsomina L.</creatorcontrib><creatorcontrib>Wark, John D.</creatorcontrib><title>Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease</title><title>Rheumatology international</title><addtitle>Rheumatol Int</addtitle><addtitle>Rheumatol Int</addtitle><description>Bisphosphonates such as alendronate, risedronate and zoledronate have revolutionised the treatment for osteoporosis and Paget’s disease. These drugs reduce fracture risk and probably mortality in patients with osteoporosis. However, they have a long in vivo half-life following cessation and may be associated with delayed dental healing and even the devastating complication of osteonecrosis of the jaw (ONJ). Extensive media attention highlighting this issue has caused much concern among patients and healthcare professionals. This paper seeks to provide treating clinicians with a balanced multi-disciplinary review of the available evidence pertaining to this issue and practical advice regarding prevention and management of ONJ.</description><subject>Animals</subject><subject>Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology</subject><subject>Bisphosphonate-Associated Osteonecrosis of the Jaw - prevention & control</subject><subject>Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy</subject><subject>Bone Density - drug effects</subject><subject>Disease Models, Animal</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Review</subject><subject>Rheumatology</subject><issn>0172-8172</issn><issn>1437-160X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kE1LxDAQhoMo7rr6A7xIwYuXaCbpJu1RF79gxYuCt5C0090ubbI2XcR_b8quIoKHmSHkmXdmXkJOgV0CY-oqMMZzSRkIypUCqvbIGFKhKEj2tk_GDBSnWUwjchTCisW3lOyQjLiQU65yNiZPN3VYL_0QzvRIO2xiKRMfevQOi86HOiS-SvolJivzkdQucd7R1jT1whnXJzZiSVkHNAGPyUFlmoAnuzohr3e3L7MHOn--f5xdz2mRptDTEkBWJeSp5UU8QAFywyw33IIQcUnLrCxSsGpa8UyoKktRFFO0lsksN5kUE3Kx1V13_n2DoddtHQpsGuPQb4KGlGc8shwiev4HXflN5-J2A6VEyiXjkYItNRwcOqz0uqtb031qYHrwWm-91tFrPXitVew52ylvbIvlT8e3uRHgWyDEL7fA7tfof1W_AAYniHs</recordid><startdate>20130901</startdate><enddate>20130901</enddate><creator>Wong, Peter K.</creator><creator>Borromeo, Gelsomina L.</creator><creator>Wark, John D.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20130901</creationdate><title>Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease</title><author>Wong, Peter K. ; Borromeo, Gelsomina L. ; Wark, John D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-d116fd194b2c29671e2a0b2a2b133017b0b6c41b75f2837f84e3c5ebb0689a863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology</topic><topic>Bisphosphonate-Associated Osteonecrosis of the Jaw - prevention & control</topic><topic>Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy</topic><topic>Bone Density - drug effects</topic><topic>Disease Models, Animal</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Review</topic><topic>Rheumatology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wong, Peter K.</creatorcontrib><creatorcontrib>Borromeo, Gelsomina L.</creatorcontrib><creatorcontrib>Wark, John D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wong, Peter K.</au><au>Borromeo, Gelsomina L.</au><au>Wark, John D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease</atitle><jtitle>Rheumatology international</jtitle><stitle>Rheumatol Int</stitle><addtitle>Rheumatol Int</addtitle><date>2013-09-01</date><risdate>2013</risdate><volume>33</volume><issue>9</issue><spage>2189</spage><epage>2198</epage><pages>2189-2198</pages><issn>0172-8172</issn><eissn>1437-160X</eissn><abstract>Bisphosphonates such as alendronate, risedronate and zoledronate have revolutionised the treatment for osteoporosis and Paget’s disease. These drugs reduce fracture risk and probably mortality in patients with osteoporosis. However, they have a long in vivo half-life following cessation and may be associated with delayed dental healing and even the devastating complication of osteonecrosis of the jaw (ONJ). Extensive media attention highlighting this issue has caused much concern among patients and healthcare professionals. This paper seeks to provide treating clinicians with a balanced multi-disciplinary review of the available evidence pertaining to this issue and practical advice regarding prevention and management of ONJ.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>23652790</pmid><doi>10.1007/s00296-013-2771-7</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0172-8172 |
| ispartof | Rheumatology international, 2013-09, Vol.33 (9), p.2189-2198 |
| issn | 0172-8172 1437-160X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1428268921 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Animals Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology Bisphosphonate-Associated Osteonecrosis of the Jaw - prevention & control Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy Bone Density - drug effects Disease Models, Animal Humans Medicine Medicine & Public Health Review Rheumatology |
| title | Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-01T23%3A37%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bisphosphonate-related%20osteonecrosis%20of%20the%20jaw%20in%20non-malignant%20bone%20disease&rft.jtitle=Rheumatology%20international&rft.au=Wong,%20Peter%20K.&rft.date=2013-09-01&rft.volume=33&rft.issue=9&rft.spage=2189&rft.epage=2198&rft.pages=2189-2198&rft.issn=0172-8172&rft.eissn=1437-160X&rft_id=info:doi/10.1007/s00296-013-2771-7&rft_dat=%3Cproquest_cross%3E1428268921%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1427342602&rft_id=info:pmid/23652790&rfr_iscdi=true |